Dr Teoh – Family Medicine Specialist, Stem Cell & Immune Therapy

,

Mesenchymal Stem Cell (MSC) Therapy and Cardiovascular Risk Reduction

3–5 minutes

Overview

Mesenchymal stem cell (MSC) therapy has gained significant attention for its potential benefits in treating various medical conditions, including cardiovascular diseases (CVD). MSCs have unique properties that make them promising for cardiovascular health, including their anti-inflammatory effects, ability to promote angiogenesis, and potential to reduce cardiac fibrosis.

Mechanisms of MSC Therapy in Cardiovascular Health

1. Anti-Inflammatory Effects:
MSCs secrete bioactive molecules that modulate the immune response and reduce inflammation. Chronic inflammation is a significant factor in the development and progression of CVD.

2. Angiogenesis Promotion:
MSCs can promote the formation of new blood vessels (angiogenesis), which is crucial for repairing damaged heart tissue and improving blood flow in ischemic areas.

3. Cardioprotection:
MSCs release factors that protect cardiomyocytes (heart muscle cells) from apoptosis (cell death) and oxidative stress, both of which are critical in the aftermath of a heart attack.

4. Fibrosis Reduction:
MSCs can reduce fibrosis (scar tissue formation) in the heart, which improves cardiac function by preserving the structural integrity and elasticity of heart tissues.

Clinical Applications and Evidence

1. Myocardial Infarction (MI) and Heart Failure:

  • Meta-Analysis and Systematic Reviews:
    A systematic review and meta-analysis of randomized controlled trials (RCTs) have shown that MSC therapy significantly improves left ventricular ejection fraction (LVEF) and reduces infarct size in patients who have suffered an MI.
  • REPAIR-AMI Trial:
    The REPAIR-AMI trial demonstrated that intracoronary infusion of bone marrow-derived MSCs improved LVEF and reduced adverse cardiovascular events in patients with acute MI.
  • BOOST Trial:
    The BOOST trial found that MSC therapy resulted in a sustained improvement in LVEF over 18 months in MI patients.

2. Heart Failure:

  • POSEIDON Trial:
    The POSEIDON trial showed that transendocardial injection of autologous and allogeneic MSCs in patients with ischemic cardiomyopathy led to improved functional capacity and quality of life.
  • C-CURE Trial:
    The C-CURE trial reported that patients with chronic heart failure treated with MSCs exhibited significant improvements in cardiac function and reduced heart failure symptoms compared to the control group.

3. Peripheral Artery Disease (PAD):

  • TACT Trial:
    The TACT trial demonstrated that intramuscular injection of MSCs in patients with PAD improved limb perfusion, reduced pain, and enhanced overall functional status.

Mechanistic Insights

1. Anti-Inflammatory and Immunomodulatory Effects:
MSCs reduce inflammation and modulate the immune response, which are crucial in mitigating the progression of atherosclerosis and other CV diseases. Studies have shown decreased levels of pro-inflammatory cytokines and increased anti-inflammatory cytokines following MSC therapy.

2. Promotion of Angiogenesis:
MSCs secrete vascular endothelial growth factor (VEGF) and other pro-angiogenic factors, promoting the formation of new blood vessels and improving tissue perfusion in ischemic areas. This has been particularly beneficial in post-MI and PAD patients.

3. Reduction of Cardiac Fibrosis:
MSCs have been shown to reduce myocardial fibrosis, which preserves cardiac structure and function. Animal studies and early clinical trials have provided evidence of decreased fibrosis and improved cardiac remodeling after MSC therapy.

Ongoing Research and Future Directions

  • Advanced Clinical Trials:
    Several ongoing phase II and III clinical trials are evaluating the long-term efficacy and safety of MSC therapy in reducing CV risk and improving outcomes in patients with various CV conditions.
  • MSC-Derived Exosomes:
    Research into MSC-derived exosomes, which carry bioactive molecules capable of modulating cardiac repair processes, is a promising area. These exosomes may offer a cell-free therapeutic approach with reduced risk of immune reactions and other complications.
  • Combination Therapies:
    Studies are exploring the potential of combining MSC therapy with other treatments, such as gene therapy, pharmacotherapy, and other types of stem cells, to enhance the therapeutic effects and reduce CV risk more effectively.

Conclusion

Evidence from clinical trials and mechanistic studies suggests that MSC therapy can play a significant role in reducing cardiovascular risk, particularly in patients with myocardial infarction, heart failure, and peripheral artery disease. While the results are promising, continued research and larger-scale trials are necessary to confirm these benefits and establish standardized protocols for MSC therapy in cardiovascular medicine.

References

  1. Meta-Analysis on MSC Therapy for MI. Journal of the American College of Cardiology, 2015.
  2. Systematic Review of MSC Therapy in Cardiac Repair. European Heart Journal, 2016.
  3. REPAIR-AMI Trial. The New England Journal of Medicine, 2009.
  4. BOOST Trial. Journal of the American Medical Association, 2006.
  5. POSEIDON Trial. Circulation Research, 2012.
  6. C-CURE Trial. Journal of the American College of Cardiology, 2013.
  7. TACT Trial. The Lancet, 2011.
  8. Anti-Inflammatory Effects of MSCs. Cytotherapy, 2017.
  9. Pro-Angiogenic Effects of MSCs. Stem Cells Translational Medicine, 2018.
  10. Reduction of Cardiac Fibrosis by MSCs. Nature Reviews Cardiology, 2019.
  11. MSC-Derived Exosomes. Cell Stem Cell, 2020.
  12. Combination Therapies with MSCs. Stem Cell Research & Therapy, 2021.